Open AccessSummary of the NACI Update on the recommended use of Human Papillomavirus (HPV) vaccine: Nine-valent HPV vaccine two-dose immunization schedule and the use of HPV vaccines in immunocompromised populations
Author(s) -
S L Deeks,
Tunis Mc,
Shainoor J. Ismail
Publication year - 2017
Publication title -
canada communicable disease report
Language(s) - English
Resource type - Journals
eISSN - 1481-8531
pISSN - 1188-4169
DOI - 10.14745/ccdr.v43i07a04
Subject(s) - immunization , medicine , vaccination , hpv vaccines , human papillomavirus , human papillomavirus vaccine , schedule , vaccination schedule , immunology , virology , hpv infection , cervical cancer , cancer , immune system , gardasil , computer science , operating system
Human papillomavirus (HPV) infections are the most common sexually transmitted infections. In the absence of vaccination, it is estimated that 75% of sexually active Canadians will have an HPV infection at some point in their lives. HPV vaccine programs were first recommended by Canada's National Advisory Committee on Immunization (NACI) in 2007. In addition to the existing HPV vaccine options in Canada, NACI recently recommended the use of a newly authorized nine-valent HPV (HPV9) vaccine according to a 3-dose immunization schedule for the prevention of HPV types 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52- and 58-related cancers and anogenital warts in females aged 9 to 45 years and males aged 9 to 26 years. New data have emerged evaluating a 2-dose immunization schedule for HPV9 vaccine in males and females, which NACI reviewed in order to provide timely guidance on the possibility of a 2-dose immunization schedule for HPV9 vaccine. Recently, a growing number of studies have also specifically explored the responses of immunocompromised subgroups to HPV vaccines, which also triggered a NACI literature review and updated recommendations on this topic.